Figure 1.

Tumor volume in athymic mice bearing subcutaneously transplanted DU-145 human androgen-independent prostate cancers after treatment with the GH-RH antagonist MZ-5-156 administered s.c. at a dose of 20 μg per animal twice a day (b.i.d.). Treatment was started when tumors measured approximately 40–50 mm³ and lasted for 8 weeks. Vertical lines indicate the SEM. ∗, P < 0.05; ∗∗, P < 0.01 versus control.